Status:
UNKNOWN
Diagnostic Value of AFP-L3 and PIVKA-II in HCC
Lead Sponsor:
Hanoi Medical University
Collaborating Sponsors:
Bach Mai Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-85 years
Brief Summary
The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The stu...
Detailed Description
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-...
Eligibility Criteria
Inclusion
- Age between 18 and 85
- Receiving no treatment before diagnosis
- Establishing Diagnosis according to thecriteria of Ministry of Public Health of Vietnam 2012.
Exclusion
- Clinical data missing
- Laboratory tests information missing
- Serum samples doesn't qualified
- Obstructive jaundice patients
- Medical history of taking warfarin
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03460080
Start Date
January 1 2018
End Date
December 1 2018
Last Update
March 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanoi Medical University
Hanoi, Vietnam, 100000